Expert Review of Anti-infective Therapy最新文献_第9页

Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection. 揭示微/纳米生物材料在治疗幽门螺旋杆菌感染中的潜在作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-29 DOI: 10.1080/14787210.2024.2391910

Misagh Fathi Kisomi, Abbas Yadegar, Tara Shekari, Mohsen Amin, Antoni Llopis-Lorente, Chenguang Liu, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Ali Shokrgozar, Mohammad Reza Zali, Mazda Rad-Malekshahi, Amir Hossein Miri, Michael R Hamblin, Matthias G Wacker

{"title":"Unveiling the potential role of micro/nano biomaterials in the treatment of Helicobacter pylori infection.","authors":"Misagh Fathi Kisomi, Abbas Yadegar, Tara Shekari, Mohsen Amin, Antoni Llopis-Lorente, Chenguang Liu, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Ali Shokrgozar, Mohammad Reza Zali, Mazda Rad-Malekshahi, Amir Hossein Miri, Michael R Hamblin, Matthias G Wacker","doi":"10.1080/14787210.2024.2391910","DOIUrl":"10.1080/14787210.2024.2391910","url":null,"abstract":"Introduction: Helicobacter pylori causes stubborn infections and leads to a variety of stomach disorders, such as peptic ulcer, chronic atrophic gastritis, and gastric cancer. Although antibiotic-based approaches have been widely used against H. pylori, some challenges such as antibiotic resistance are increasing in severity. Therefore, simpler but more effective strategies are needed.Areas covered: In this review, basic information on functionalized and non-functionalized micro/nano biomaterials and routes of administration for H. pylori inhibition are provided in an easy-to-understand format. Afterward, in vitro and in vivo studies of some promising bio-platforms including metal-based biomaterials, biopolymers, small-molecule saccharides, and vaccines for H. pylori inhibition are discussed in a holistic manner.Expert opinion: Functionalized or non-functionalized micro/nano biomaterials loaded with anti-H. pylori agents can show efficient bactericidal activity with no/slight negative influence on the host gastrointestinal microbiota. However, this claim needs to be substantiated with hard data such as assessment of the biopharmaceutical parameters of anti-H. pylori systems and the measurement of diversity/abundance of bacterial genera in the host gastric/gut microbiota before and after H. pylori eradication.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"613-630"},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease. 口服抗病毒药物治疗非住院COVID-19慢性肾病患者的临床效果。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-03-26 DOI: 10.1080/14787210.2024.2334052

Chia-Chen Chen, Chi-Ya Huang, Jheng-Yan Wu, Mei-Yuan Liu, Min-Hsiang Chuang, Ting-Hui Liu, Ya-Wen Tsai, Wan-Hsuan Hsu, Po-Yu Huang, Ming-Hui Chen, Su-Yen Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Chih-Cheng Lai, I-Ning Yang

{"title":"Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease.","authors":"Chia-Chen Chen, Chi-Ya Huang, Jheng-Yan Wu, Mei-Yuan Liu, Min-Hsiang Chuang, Ting-Hui Liu, Ya-Wen Tsai, Wan-Hsuan Hsu, Po-Yu Huang, Ming-Hui Chen, Su-Yen Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Chih-Cheng Lai, I-Ning Yang","doi":"10.1080/14787210.2024.2334052","DOIUrl":"10.1080/14787210.2024.2334052","url":null,"abstract":"Objectives: This study examined the effectiveness of nirmatrelvir plus ritonavir (NMV-r) and molnupiravir (MOV) in treating COVID-19 among chronic kidney disease (CKD) patients.Methods: This retrospective cohort study, using the TriNetX research network, identified stage 3-5 CKD and end-stage kidney disease (ESKD) patients with non-hospitalized COVID-19 between 1 January 2022, and 31 May 2023. Propensity score matching (PSM) was used to compare patients on NMV-r or MOV (antiviral group) against those not receiving these treatments (control group). The primary composite outcome was the cumulative hazard ratio (HR) for all-cause hospitalization or death within the 30-day follow-up.Results: After PSM, two balanced cohorts of 6,275 patients each were established. The antiviral group exhibited a lower incidence of all-cause hospitalization or mortality (5.93% vs. 9.53%; HR: 0.626; 95% CI: 0.550-0.713) than controls. Additionally, antiviral recipients were associated with a lower risk of all-cause hospitalization (HR: 0.679; 95% CI: 0.594-0.777) and mortality (HR: 0.338; 95% CI: 0.227-0.504). The beneficial effects of antiviral agents were consistent across sex, age, vaccination status, antiviral type, and CKD stage.Conclusion: Oral antiviral agents could be associated with lower rates of all-cause hospitalization or death among non-hospitalized COVID-19 patients with CKD.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"705-712"},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of truenat assays for the diagnosis of pulmonary and extrapulmonary tuberculosis: a systematic review and meta-analysis. 用于诊断肺部和肺部外结核病的真菌检测评估：系统综述和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-11 DOI: 10.1080/14787210.2024.2389876

Shima Mahmoudi, Amir Hossein Sadegh Moghaddasi

{"title":"Evaluation of truenat assays for the diagnosis of pulmonary and extrapulmonary tuberculosis: a systematic review and meta-analysis.","authors":"Shima Mahmoudi, Amir Hossein Sadegh Moghaddasi","doi":"10.1080/14787210.2024.2389876","DOIUrl":"10.1080/14787210.2024.2389876","url":null,"abstract":"Background: Tuberculosis (TB) remains a significant global health concern, necessitating accurate and timely diagnostic methods. This study aimed to conduct a systematic review and meta-analysis to assess the diagnostic accuracy of Truenat assays for both pulmonary TB (PTB) and extrapulmonary TB (EPTB).Method: PubMed, Scopus, and Web of Science were systematically searched for studies comparing Truenat assays to Mycobacterium tuberculosis confirmation methods.Results: Comparing Truenat MTB assay with the Lowenstein-Jensen (LJ) culture, the pooled sensitivity and specificity were 86% (95% CI: 79-91%) and 86% (95% CI: 82-90%), respectively. For Mycobacterial Growth Indicator Tube (MGIT) culture comparison, pooled sensitivity was 88% (95% CI: 82-92%) with a specificity of 79% (95% CI: 57-92%). Compared to smear microscopy, Truenat assays displayed pooled sensitivity and specificity of 92% (95% CI: 78-98%) and 86% (95% CI: 64-95%). In comparison to Xpert MTB/RIF, Truenat assays exhibited a pooled sensitivity of 92% (95% CI: 80-97%) and a pooled specificity of 92% (95% CI: 56-99%) for PTB detection, and a pooled sensitivity of 94% (95% CI: 81-98%) and a specificity of 77% (95% CI: 32-96%) for the diagnosis of EPTB.Conclusion: This study underscores the potential of Truenat assays as valuable tools for diagnosing both PTB and EPTB.Prospero id: CRD42024526686.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"659-668"},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of supplementation with low-dose group B vitamins on clinical and biochemical parameters in critically ill patients with COVID-19: a randomized clinical trial. 补充小剂量 B 族维生素对 COVID-19 重症患者临床和生化指标的影响：随机临床试验。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-01 Epub Date: 2022-09-28 DOI: 10.1080/14787210.2022.2125867

Nazanin Majidi, Effat Bahadori, Soheila Shekari, Maryam Gholamalizadeh, Shirin Tajadod, Marjan Ajami, Somayeh Gholami, Mahdi Shadnoush, Mina Ahmadzadeh, Anoush Dehnadi Moghadam, Naeemeh Hassanpour Ardekanizadeh, Hanieh Shafaei Kachaei, Fatemeh Shafie, Alireza Moslem, Saeid Doaei, Mark O Goodarzi

{"title":"Effects of supplementation with low-dose group B vitamins on clinical and biochemical parameters in critically ill patients with COVID-19: a randomized clinical trial.","authors":"Nazanin Majidi, Effat Bahadori, Soheila Shekari, Maryam Gholamalizadeh, Shirin Tajadod, Marjan Ajami, Somayeh Gholami, Mahdi Shadnoush, Mina Ahmadzadeh, Anoush Dehnadi Moghadam, Naeemeh Hassanpour Ardekanizadeh, Hanieh Shafaei Kachaei, Fatemeh Shafie, Alireza Moslem, Saeid Doaei, Mark O Goodarzi","doi":"10.1080/14787210.2022.2125867","DOIUrl":"10.1080/14787210.2022.2125867","url":null,"abstract":"Background: : This study aimed to check the effect of supplementation with low-dose group B vitamins on clinical and biochemical parameters on patients with coronavirus disease 2019 (COVID-19).Research design and method: : This double-blind, randomized clinical trial was carried out on 85 critically ill patients with COVID-19. All patients received high protein prescriptions of 30 kcal/kg/d by enteral nutrition. The intervention group (n = 40) received vitamin B complex, including thiamine (10 mg), riboflavin (4 mg), nicotinamide (40 mg), and dexpanthenol (6 mg). The control group received similar nutritional supports, except for group B vitamins. Assessments were carried out at baseline and after 2 weeks of intervention.Results: : Vitamin B supplementation had no effects on the biochemical and pathological parameters including kidney function, arterial blood gas parameters, Glasgow coma scale, cell blood count, and serum electrolytes of the intervention group compared with the control group. The 30-day mortality was insignificantly lower in the intervention group than in the control group (83.3% against 96.1%, P = 0.07).Conclusions: The mortality rate of patients with COVID-19 might be improved by low-dose vitamin B supplementation.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"579-585"},"PeriodicalIF":4.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis. 尼马瑞韦/利托那韦与索妥单抗治疗 COVID-19 的有效性和安全性比较：系统综述和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-01 Epub Date: 2024-03-08 DOI: 10.1080/14787210.2024.2326561

Behnam Amani, Bahman Amani

{"title":"Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis.","authors":"Behnam Amani, Bahman Amani","doi":"10.1080/14787210.2024.2326561","DOIUrl":"10.1080/14787210.2024.2326561","url":null,"abstract":"Background: This study aims to compare the effectiveness and safety of nirmatrelvir/ritonavir (Paxlovid) and sotrovimab for coronavirus disease 2019 (COVID-19).Methods: A search was conducted on PubMed, Cochrane Library, and Web of Science to explore relevant studies from January 2021 to November 2023. The risk of bias in the included studies was assessed using the Cochrane Collaboration's tool. Data analysis was conducted using the Comprehensive Meta-Analysis software (version 3.0).Results: Fifteen retrospective studies involving 13, 306 patients were included. The meta-analysis revealed no significant difference between the nirmatrelvir/ritonavir and sotrovimab groups in terms of mortality rate (odds ratio [OR] = 0.62, 95% confidence interval [CI]: 0.28 to 1.38), hospitalization rate (OR = 0.76, 95% CI: 0.48 to 1.22), death or hospitalization rate (OR = 0.75, 95% CI: 0.51 to 1.10), and intensive unit care admission (OR = 1.97, 95% CI: 0.38 to 10.07). In terms of safety, nirmatrelvir/ritonavir was associated with a higher incidence of adverse events (OR = 3.44, 95% CI: 1.29 to 9.17).Conclusions: The meta-analysis showed that nirmatrelvir/ritonavir and sotrovimab have similar effectiveness in treating COVID-19 patients. However, the certainty of evidence supporting these findings is low. High-quality research is needed to better compare these interventions in COVID-19.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"547-555"},"PeriodicalIF":4.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140059058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19. 中药 NRICM101 在 COVID-19 住院患者中的临床应用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-01 Epub Date: 2024-02-02 DOI: 10.1080/14787210.2024.2313054

Wen-Kuei Chang, Chieh-Jen Wang, Tung-Hu Tsai, Fang-Ju Sun, Chao-Hsien Chen, Kuan-Chih Kuo, Hsin-Pei Chung, Yen-Hsiang Tang, Yen-Ting Chen, Kuo-Lun Wu, Jou-Chun Wu, Chang-Yi Lin, Hai-Bo Zhang

{"title":"The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19.","authors":"Wen-Kuei Chang, Chieh-Jen Wang, Tung-Hu Tsai, Fang-Ju Sun, Chao-Hsien Chen, Kuan-Chih Kuo, Hsin-Pei Chung, Yen-Hsiang Tang, Yen-Ting Chen, Kuo-Lun Wu, Jou-Chun Wu, Chang-Yi Lin, Hai-Bo Zhang","doi":"10.1080/14787210.2024.2313054","DOIUrl":"10.1080/14787210.2024.2313054","url":null,"abstract":"Background: The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19.Research design and methods: We conducted a retrospective study from 20 April 2021 to 8 July 2021, and evaluated the safety and outcomes (mortality, hospital stay, mechanical ventilation, oxygen support, diarrhea, serum potassium) in COVID-19 patients. Propensity score matching at a 1:2 ratio was performed to reduce confounding factors.Results: A total of 201 patients were analyzed. The experimental group (n = 67) received NRICM101 and standard care, while the control group (n = 134) received standard care alone. No significant differences were observed in mortality (10.4% vs. 14.2%), intubation (13.8% vs. 11%), time to intubation (10 vs. 11 days), mechanical ventilation days (0 vs. 9 days), or oxygen support duration (6 vs. 5 days). However, the experimental group had a shorter length of hospitalization (odds ratio = 0.12, p = 0.043) and fewer mechanical ventilation days (odds ratio = 0.068, p = 0.008) in initially severe cases, along with an increased diarrhea risk (p = 0.035).Conclusion: NRICM101 did not reduce in-hospital mortality. However, it shortened the length of hospitalization and reduced mechanical ventilation days in initially severe cases. Further investigation is needed.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"587-595"},"PeriodicalIF":4.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing prolonged infusion to intermittent infusion strategies for beta-lactam antibiotics in patients with gram-negative bacterial infections: a systematic review and meta-analysis. 革兰氏阴性菌感染患者长期输注和间歇性输注β-内酰胺类抗生素策略的比较：系统综述和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-01 Epub Date: 2024-03-05 DOI: 10.1080/14787210.2024.2324940

Chih-Chung Lin, Jheng-Yen Wu, Po-Yu Huang, Hui-Lin Sung, Yu-Chun Tung, Chih-Cheng Lai, Yu-Feng Wei, Pin-Kuei Fu

{"title":"Comparing prolonged infusion to intermittent infusion strategies for beta-lactam antibiotics in patients with gram-negative bacterial infections: a systematic review and meta-analysis.","authors":"Chih-Chung Lin, Jheng-Yen Wu, Po-Yu Huang, Hui-Lin Sung, Yu-Chun Tung, Chih-Cheng Lai, Yu-Feng Wei, Pin-Kuei Fu","doi":"10.1080/14787210.2024.2324940","DOIUrl":"10.1080/14787210.2024.2324940","url":null,"abstract":"Introduction: Our objective is to determine whether prolonged infusion (PI) of beta-lactam antibiotics yields superior outcomes compared to intermittent infusion (II) in patients with Gram-Negative Bacterial (GNB) infections.Methods: We systematically searched papers from PubMed, the Cochrane Library, Embase, and Clinicaltrials.gov, targeting mortality as the primary outcome and looking at the clinical cure rate, hospital and intensive care unit (ICU) stay lengths, antibiotic treatment duration, and mechanical ventilation (MV) duration as secondary outcomes.Results: Our meta-analysis of 18 studies, including 5 randomized control trials and 13 observational studies, with a total of 3,035 patients-1,510 in the PI group and 1,525 in the II group, revealed significant findings. PI was associated with reduced mortality (RR, 0.67; 95% CI, 0.55-0.81; p = 0.001; I2 = 4.52%) and a shorter MV duration (SMD, -0.76; 95% CI, -1.37 to -0.16; p = 0.01; I2 = 87.81%) compared to II. However, no differences were found in clinical cure rates, antibiotic treatment duration, length of hospital stay, or length of ICU stay.Conclusions: The PI approach for administering beta-lactam antibiotics in patients with suspected or confirmed GNB infections may be advantageous in reducing mortality rates and the duration of MV when compared to the II strategy.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"557-567"},"PeriodicalIF":4.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-01 Epub Date: 2024-06-18 DOI: 10.1080/14787210.2024.2370086

引用次数: 0

Analysis of antimicrobial drug usage in psychiatric specialized hospitals during the pandemic in China. 中国大流行期间精神病专科医院抗菌药物使用情况分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-01 Epub Date: 2024-05-08 DOI: 10.1080/14787210.2024.2351022

Zhiqiang Du, Qin Zhou, Yuan Shen, Rongrong Lu, Ying Jiang, Haohao Zhu

{"title":"Analysis of antimicrobial drug usage in psychiatric specialized hospitals during the pandemic in China.","authors":"Zhiqiang Du, Qin Zhou, Yuan Shen, Rongrong Lu, Ying Jiang, Haohao Zhu","doi":"10.1080/14787210.2024.2351022","DOIUrl":"10.1080/14787210.2024.2351022","url":null,"abstract":"Background: This study aims to compare antimicrobial drug usage in our hospital to Jiangsu Province and China from 2020 to 2022.Research design and methods: A detailed analysis was performed using data from the National Antimicrobial Drug Clinical Application Monitoring Network. Several parameters were studied: the rate of antimicrobial drug use, number and types of drugs used, the rate of combined use, rate of microbiological examinations, drug use intensity, and cumulative Defined Daily Doses (DDDs).Results: From 2020 to 2022, our hospital's antimicrobial drug usage rate was consistently lower than Jiangsu Province and China. The average number of drug types and the combined drug use rate were higher in 2020 but fell below those in Jiangsu Province and China in 2021 and 2022. Our microbiological examination rate consistently surpassed that of Jiangsu Province and China. Furthermore, our Antimicrobial Usage Density and cumulative DDDs were notably lower. While AUD remained stable, DDDs showed a decreasing trend. The most dominant drug in DDDs was cefditoren, a third-generation cephalosporin.Conclusions: During the pandemic years, our hospital not only met the requirements for antimicrobial drug usage, microbiological examination, AUD, and cumulative DDDs but also demonstrated a consistent year-by-year decrease in drug usage and DDDs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"597-602"},"PeriodicalIF":4.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140850169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of β-defensins against infectious pathogenic microorganisms. 针对传染性病原微生物的β防御素应用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-07-01 Epub Date: 2024-07-09 DOI: 10.1080/14787210.2024.2377677

Xiuyun Li, Xiaoming Wang, Jiajing Du, Xiangzhen Bu, Chao Peng, Ximeng Duan, Chen Fu

{"title":"Applications of β-defensins against infectious pathogenic microorganisms.","authors":"Xiuyun Li, Xiaoming Wang, Jiajing Du, Xiangzhen Bu, Chao Peng, Ximeng Duan, Chen Fu","doi":"10.1080/14787210.2024.2377677","DOIUrl":"10.1080/14787210.2024.2377677","url":null,"abstract":"Introduction: Antimicrobial peptides (AMPs) are polypeptides with potent antimicrobial activity against a broad range of pathogenic microorganisms. Unlike conventional antibiotics, AMPs have rapid bactericidal activity, a low capacity for inducing resistance, and compatibility with the host immune system. A large body of data supports the antimicrobial activities of a large body of data supports the antimicrobial activities of the class of AMPs known as β-defensins. This review provides a comprehensive analysis of the effects of β-defensins against various pathogenic microorganism: bacteria, fungi, viruses, Mycoplasmas and Chlamydiae. The primary mechanisms of β-defensins against pathogenic microorganisms include inhibition of biofilms formations, dissolution of membranes, disruption of cell walls, and inhibition of adhesion and receptor binding. Although further study and structural modifications are needed, β-defensins are promising candidates for antimicrobial therapy.Areas covered: This review describes the inhibitory effects of β-defensins on various pathogenic microorganisms. Additionally, we focus on elucidating the mechanisms underlying their actions to provide, providing valuable references for the further study of β-defensins.Expert opinion: The biological activities and modes of action of β-defensins provide powerful resources for clinical microbial infection management. Addressing the salt sensitivity and toxicity of β-defensins may further enhance their potential applications.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"501-510"},"PeriodicalIF":4.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0